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Abstract 
Cadherin and catenin-family proteins regulate adhesion in malignant melanoma.  
Using AQUA (Automated Quantitative Analysis) to quantitate the levels of alpha-
catenin, beta-catenin, p120-catenin, N-cadherin, E-cadherin, and P-cadherin in melanoma 
on tissue microarrays (TMA’s), we classified 513 patients by protein expression using 
hierarchical clustering and regression analysis.  The dendrogram supported positive 
correlations seen upon Spearman rho analysis of P-cadherin and beta-catenin (r=0.5238, 
p<0.0001) and negative, weak association of N-cadherin with other markers.  Patients 
with high expression of N-cadherin had the highest 20-year survival rate (p=0.0003).   
Our adherens protein molecular classification of melanoma defines at least two 
distinctive sub-populations of melanoma patients, those with high expression of N-
cadherin and those with low expression who have decreased survival.  These findings 
extend previous cDNA array-based findings of an epithelioid class and neural crest class 
of melanomas.   
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Introduction 
Melanoma is predicted to take the lives of approximately 7,910 patients in the 
United States in 2006, according to the American Cancer Society’s age-adjusted 
statistics.  62,190 people will be diagnosed with the deadly malignancy, 49,710 of those 
will have melanoma in situ.  According to the National Cancer Institute Surveillance, 
Epidemiology and End Results (SEER) the incidence rate is increasing by 2.8% each year 
(1981-2002), which is fortunately on the decline from a previously increasing rate of 
6.1% (1981-2002) (1).  The lifetime risk of developing melanoma for men is now 
predicted to be 1 in 52 — and for women 1 in 77 (2).   
Although melanoma can be a very serious cancer, the survival rates have been 
increasing in recent years.  The relative 5-year survival rate for all races between 1995-
2001 was 92%, increased from 85% between 1983-1985, and 80% between 1974-
1976(1,2).  The death rates in white women have been decreasing since 1988, and for 
men they have been on a decline since 1998.  Although trends from the recent past are 
showing encouraging new developments, melanoma is still the fifth most common cancer 
in incidence for men and the sixth most common for woman in the United States (2).  
Melanoma is the third leading cancer in Incidence Percent Change from 1992-2002 at 
over 20% risk and over 40% burden for all ages (1).   
 
Melanoma Staging Systems 
Statistics show that melanoma proves itself as a deadly malignancy.  To 
determine treatment and prognosis, staging systems provide some ammunition in this 
difficult fight.  Physicians depend on these algorithms to determine how, when, and 
where (locally or systemically) to treat.  Besides guiding treatment, the evidence-based 
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systems are necessary to estimate survival.  Physicians have made great strides to create 
an accurate melanoma staging system, but the current standards have fallen short of our 
expectations.  When diagnosing malignant melanoma, physicians are forced to provide 
wide-ranging survival estimates.  Balch et al. showed that 10-year survival estimates in 
stage II melanoma range from 50.8% ± 1.7 to 64.4% ± 2.2 and that stage III cancers 
range from 18.4% ± 2.5 to 63.0% ± 4.4(3).  Although predictive of survival, these broad 
survival estimates are the basis for the most recent American Joint Commission of 
Cancer (AJCC) staging system.   The most recent changes were adopted in 2002, and the 
current guidelines are based on tumor thickness, nodal involvement, and distant 
metastasis.  The requirements are shown below: 
 
Table 1. TNM Classification of Melanoma (adapted from Kim et al. (4)).  
Tumor (T) Classification Thickness (Breslow) Presence of Ulceration 
T1 < or = 1.0 mm a: without ulceration 
b: with ulceration or Clark level 
IV or V 
T2 1.01-2.0 mm a: without ulceration 
b: with ulceration 
T3 2.0-4.0 mm a: without ulceration 
b: with ulceration 
T4 >4.0 mm a: without ulceration 
b: with ulceration 
Node (N) Classification Number of involved lymph 
nodes 
Level of lymph node 
involvement 
N1 1 lymph node a: micrometastasis 
b: macrometastasis 
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N2 2-3 lymph nodes a: micrometastasis 
b: macrometastasis 
N3 >4 metastatic lymph nodes, 
matted LN, or in-transit 
met(s)/satellite(s) and metastatic 
lymph nodes 
a: micrometastasis 
b: macrometastasis 
c: in-transit met(s)/satellite(s) 
without metastatic lymph nodes 
Metastasis (M) 
Classification 
Site of Metastasis Serum LDH Level 
M1 Distant skin, subcutaneous, or 
lymph node metastases 
Normal LDH 
M2 Lung metastases Normal LDH 
M3 All other visceral or distant 
metastases 
Normal LDH or elevated LDH 
 
 
Table 2.  AJCC Melanoma Stage Groupings (adapted from Kim et al. (4)). 
Stage T N M 
0 Tis (in situ) N0 M0 
IA T1a N0 M0 
IB T1b 
T2a 
N0 M0 
IIA T2b 
T3a 
N0 
N0 
M0 
M0 
IIB T3b 
T4a 
N0 
N0 
M0 
M0 
IIC T4b N0 M0 
IIIA-C Any T N1 or N2 or N3 M0 
IV Any T Any N Any M1 
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Sentinel Lymph Node Biopsy 
 Since melanoma staging depends on the number of involved lymph nodes, a 
sentinel lymph node biopsy (SLNB) is a core requirement for complete diagnosis if the 
tumor depth is greater than 1 mm.  Messina et al. showed that immunohistochemistry 
staining for S100 in the lymph nodes identified an additional 36% of detected metastatic 
disease than just hematoxylin and eosin stain alone (5).   
In 2006, Morton et al. tried to further strengthen the argument that the sentinel 
lymph node biopsy improves survival.  They showed that in 1269 patients the disease-
free survival rate was 78.3% for the SLNB group and only 73.1% for the observation 
group (6).  Although these numbers are significantly different, it is difficult to argue that 
an increase survival of 5% is a monumental achievement.  The study’s melanoma specific 
death rate was nearly the same for both groups at 5 years (12.5% for SLNB patients and 
13.8% for observation patients) suggesting that the effect of the SLNB may not be as 
powerful as originally believed.  Their results confirm that SLNB’s are useful to 
accurately stage melanoma.  However, the authors state that early SLNB can also 
improve disease-free survival (6).  This appears true based on their results, but when all 
the results are carefully weighed, the slight improved survival is not reflected in the 
melanoma death rate.  For their hypothesis that SLNB improves survival to hold true, the 
effects should be seen across all statistical methods of assessing improved survival. 
Lymph node tissue has been the primary material/target for molecular 
classification of melanoma to date.   Researchers stain tissue for S-100 and HMB45, and 
perform PCR analysis (7).  The problem with new models of classification is the process 
of obtaining lymph node tissue—a SLNB is required.  Since melanoma is a deadly 
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disease, physicians are willing to offer the best possible treatment even if it requires 
exposing the patient to new risks such as further surgical complications.  Sentinel lymph 
node biopsy is recommended for tumors >1.0 mm, but has had questionable merit in the 
management of melanoma for tumors <1.0 mm.  Ranieri suggests that melanomas >0.75 
mm have a metastatic rate of 6.5%, and select patients with other risk factors such as high 
mitotic activity should undergo SLNB (8).  The procedure remains one of the crucial 
components of our current American Joint Committee of Cancer (AJCC) melanoma 
staging system (Tables 1 and 2) (9).  Any nodal involvement elevates the cancer to stage 
III.  Prognosis estimates using the current system give wide-ranging survival estimates.  
For example, patients with stage III cancers have survival rates ranging from 18.4% ± 2.5 
to 63.0% ± 4.4 (3).    These wide ranging estimates are not acceptable.  Although few 
effective adjuvant melanoma therapies exist, we should set out to find further methods to 
refine the staging of melanoma. 
One possible method for determining better survival estimates is the use of 
molecular classification on primary and metastatic tissue.  If clinicians are able to 
molecularly classify primary tissue into different levels of disease, we could forgo the 
need for invasive SLNB’s. 
 
Molecular Classification of Melanoma 
Advances in quantification technologies and analysis algorithms have allowed 
molecular classification of melanoma on a number of small cohorts.  By measuring 
mRNA expression, Bittner et al. separated a cohort of melanoma patients into groups 
characterized by motility and invasiveness.  Although the model was not designed to 
 - 6 - 
relate findings to prognosis, they found that identifying homogenous subpopulations of 
melanoma patients might allow for better prognosis estimates or possibly more precise 
treatment for subtypes of melanoma (10).  Since these findings, two classes of uveal 
melanoma have been defined based on gene expression:  a “neural crest/melanocyte” 
class and a more aggressive “epithelial” class.  The epithelial class is noted to have 
membranous staining of E-cadherin and beta-catenin and poor prognosis estimates (11).   
Other studies have shown that an assortment of genes have variable expression on DNA 
microarrays when comparing the changes that might occur as a melanocyte changes into 
a malignant melanoma.  The genetic transformations altered protein translation, which 
was confirmed by measuring protein expression.  They investigated genes and proteins 
involved in: the NOTCH pathway, regulation of transcription, immune modulation, 
membrane-trafficking, growth suppression as well as many other cellular processes (12).   
In another study using comparative genomic hybridization, Bastian et al. classified thirty 
cases of melanoma.  They used fluorescence in situ hybridization to determine that 
genomic amplification occurs well-outside the histologically demarcated tumor area in 
acral melanomas.  They demonstrated that genomic changes seen in invasive melanoma 
are present in earlier stages of melanoma progression, by showing the same molecular 
aberrations in melanoma in situ (13).  Therefore, by classifying tumors molecularly, sub-
types of melanoma can be distinguished even in the very beginning stages of 
carcinogenesis.   
Alonso and colleagues have completed the most significant study of this type 
using tissue microarrays to molecularly classify melanoma.  The examined expression of 
thirty-nine markers on 165 cases of melanoma, evaluating cell cycle and apoptosis related 
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proteins in a qualitative manner.  They created a four-marker predictor model that was 
validated with a different cohort and was found to be predictive independent of Breslow 
depth of invasion (14).  However, they did not use a quantitative form of 
immunohistochemistry and used only seventy-two melanoma cases to validate their 
predictor model.  Our work will build on these findings by quantitating differences in 
protein expression to classify a larger cohort of patients into prognostic groups. 
Using immunohistochemistry on tissue microarrays to classify melanoma has 
many advantages such as the ability to work easily with a large number of samples of 
patient tissue, but the technique is limited by the quality and availability of effective 
antibodies.  During scientific exploration it is important to ask the right question, but 
even more important than asking the correct question is the attainment and validation of 
the supplies used to seek the correct answer. 
 
Treatment of Metastatic Melanoma 
 The standard of care as a primary modality of treatment for malignant melanoma 
is surgical resection of the tumor with boundaries of 2 mm for those with melanoma of > 
4.0 mm in thickness (15,16).   Many feel that SLNB is also part of the standard of care to 
date (15,17).   Patients with local recurrence or metastatic disease should receive adjuvant 
therapy (15). 
 Most adjuvant therapies for stage IV metastatic melanoma patients are still in 
investigational stages, and the few forms of therapy that have been used in practice are 
not ideal.  There is no clear treatment of choice because many of the adjuvant therapies 
only help small percentages of patients in clinical trials; patients typically respond for 
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only a few months.  However, dacarbazine and hydroxyurea are currently the only 
cytotoxic treatments approved by the FDA to treat metastatic melanoma (18).  
Hydroxyurea has not been used as commonly as dacarbazine.  The former drug’s effects 
on metastatic melanoma have been investigated for over thirty years, and although it is 
the “standard of therapy” it only shows response rates of 15-25%.  In less rigorous studies 
small percentages of patients had been shown to survive up to 6 years, but these studies 
are typically not reproducible (18).  Various studies using dacarbazine alone or in other 
regimens show median survival ranging from 4.6 to 11.9 months (19).  Although the 
survival time for patients with metastatic melanoma is only 6 to 9 months, minimal 
improvement in survival comes at a price since all medications have side effects and 
typical chemotherapeutics have very toxic side effects.  A meta-analysis of recent “level 
1” evidence studies have shown that dacarbazine as a single agent is as effective as 
multiple-drug regimens (19).  They point out that few quality of life studies have been 
completed, but typical side effects of nausea, vomiting, fatigue, neutropenia, 
thrombocytopenia, and anemia are considerably lower when taking dacarbazine as 
monotherapy verses in a 4-drug Dartmouth regimen (dacarbazine, cisplatin, carmustine 
and tamoxifen) (19).  
All current forms of cytotoxic therapy typically show low response rates of less 
than 25%.  Researchers have been creative in searching out other treatments beyond 
typical chemotherapeutics that may show efficacy.  Scientists have tried tamoxifen, 
thalidomide, interferon-alpha, and interleukin-2.  The immunomodulators have response 
rates ranging from 40-60%.  Other treatments currently under early investigation in 
mostly Phase 1 and 2 clinical trials include: sorafenib (a BRAF kinase inhibitor), human 
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anti-CTLA-4 monoclonal antibodies, anti-BCL2 antisense oligonucleotides, and integrin 
monoclonal antibodies (MEDI-522) (18). 
 A very recent Phase II study employing the use of dacarbazine as well as two 
immunomodulators interleukin-2 and interferon-alpha, has shown one of the best 
response rates and most promising survival effects to date.   They measured the size of 
metastatic tumors as well as disease-related symptoms to determine an overall response 
rate of 52%.  Median survival for partial responders was 27 months, while the few 
patients who had a complete response with remission of symptoms and disappearance of 
metastatic lesions for 4 weeks had an average survival of over 36 months.  The median 
survival of non-responders was 15 months.  Although this is a very promising study, the 
majority of patients had only a single site of metastasis in soft tissue or a lymph node 
(20).    
 In conclusion, there is no clearly effective single adjuvant therapy regimen for 
metastatic melanoma patients.  Learning more about the biology and subtypes of 
melanoma might allow us to develop more precise and effective therapies. 
 
Cadherin and Catenins in Melanoma 
Cancer metastasis is a crucial factor in determining patient prognosis.  Cells must 
detach from their surroundings, migrate to the blood stream, then grow and survive in a 
new environment.  Scientists are progressively learning which factors are important for 
each step.   For carcinoma cells to separate from neighboring cells, proteins that allow 
adherence must be downregulated or destroyed (21).  Voura et al. showed that during 
flow through the bloodstream, melanoma cells will interact with endothelial cells via 
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pseudopods and structures composed of F-actin (22).  The final steps of metastasis 
require the displaced tumor cells to “latch on” to cells in a new environment and then 
continue to grow and divide.  Our research will focus on the first stage of tumor 
metastasis during which cells detach from their surroundings by altering amounts of 
specific proteins that make up the adhesion complex.    
The adhesion complex is composed of a variety of cadherins and catenins that 
maintain the cell’s integrity with its environment.  Cadherins are calcium-mediated, 
adhesion glycoproteins that allow cell-to-cell interaction (Figure 1).  Catenins, 
cytoplasmic proteins, compose part of the adherens junction and are thought to be a part 
of the signal that assures contact inhibition.  The proteins secure the actin cytoskeleton to 
the cell membrane.  Cadherins and catenins interact to mediate cell adhesion.   E-
cadherin, as well as P-cadherin or N-cadherin, can bind directly to beta-catenin and p120-
catenin.  Beta-catenin can then bind non-actin bound alpha-catenin.  N-cadherin is 
typically found in neural cell types, while E-cadherin is associated with epithelial tissue.  
P-cadherin is typically found in embryonic tissue, but can be present elsewhere.  E-
cadherins bind to each other via homotypic interactions (23).  
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Figure 1. Cadherin and Catenin Biology. (© humpath.com adapted from 
http://www.humpath.com/IMG/jpg/adherens_junctions-2.jpg). 
 
Numerous malignancies including carcinoma of the esophagus, colon, stomach, 
and breast have shown decreased levels of cadherin and catenin proteins when compared 
to normal tissue particularly in more aggressive tumors (24-26).   
Melanoma follows a similar pattern of loss of adherens junctional proteins when it 
becomes more invasive.  Decreased expression of E-cadherin in malignant melanoma 
indicates worse disease-free survival for patients (27).  Low expression of E- and P-
cadherin seem to correlate with disease progression in melanoma (28).  Unquantitated 
immunohistochemical studies show a decrease in P-cadherin from primary to metastatic 
melanoma, but no significant changes in E- or mesenchymal N-cadherin (29).  Similar 
studies show that maintaining P-cadherin expression is associated with better survival in 
small tissue microarray cohorts (30).  In reconstructed skin models P-cadherin exhibits 
decreased metastatic invasion with retained expression independent of N-cadherin (31).  
However, some studies with further refined methods of subcellular localization of marker 
expression have found that E-cadherin, P-cadherin, and beta-catenin shift between the 
nucleus, cytoplasm and membrane depending on tumor thickness and patient survival.  
They used univariate and multivariate analysis to show that membranous N-cadherin 
staining, cytoplasmic P-cadherin expression and loss of membranous E-cadherin 
correlated with thicker and more aggressive tumors (32). 
The catenins exhibit similar trends.  Alpha-catenin expression is reciprocally 
related to tumor thickness, suggesting that low alpha-catenin would correlate with a poor 
prognosis (33).  A decrease in expression of beta-catenin is seen comparing primary 
melanoma to metastatic disease (29).  A paucity of beta-catenin within carcinogenic 
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melanocytes is significantly associated with thicker tumors and decreased survival (32).  
Very few studies have investigated the role that p120-catenin plays in melanoma, but one 
study shows that p120 expression is correlated to beta-catenin expression in melanoma.   
Other correlations to tumor thickness and comparisons between primary and metastatic 
melanoma were not significant (33).  Gamma-catenin often has little to no expression in 
nevi or melanoma samples using immunohistochemistry (29,34).  Despite this progress, 
few studies show prognostic implications for immunohistochemical data and none show 
quantitated expression of nearly all classic cadherin and catenin markers in a large cohort.  
To further molecularly classify malignant melanoma, we investigated the 
relationships among alpha-catenin, beta-catenin, p120-catenin, N-cadherin, E-cadherin, 
and P-cadherin in melanoma tissue using quantifiable immunohistochemistry.  Patient 
subpopulations were created using hierarchical clustering based on protein expression 
patterns, and then further assessed for survival to answer the most important question: 
“Does molecular classification predict a patient’s length of survival?” 
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Hypothesis 
In human melanoma tissue, does the expression pattern of six adhesion complex 
proteins: α catenin, β catenin, p120-catenin, E-cadherin, N-cadherin, and P-cadherin 
classify patients into distinctive sub-populations?  Does molecular classification predict 
survival?  
 
Aims of Thesis 
Aim 1:   
First, we collected clinical information from a cohort of melanoma patients to use 
in an analysis of protein expression from primary and metastatic melanoma tissue. 
Second, we selected appropriate markers that have been previously implicated in 
the progression of melanoma through a complete literature review.  After validating the 
selected six antibodies, we measured cadherin and catenin expression in primary and 
metastatic melanoma tissue from the cohort of patients, melanoma cell lines, and nevi.  
We used immunohistochemistry on tissue micro-arrays with an automated system to 
analyze protein expression.  By staining with anti S-100 antibody concurrently with each 
marker antibody, we created a tumor mask for each sample to demarcate melanoma in 
epithelial tissue.  DAPI staining was used to distinguish nuclei from cytoplasm.  The 
overall score of protein staining was recorded. 
 
Aim 2: 
The relative levels of protein were linked and then analyzed with each patient’s 
prognostic information (using Kaplan-Meier curves, COX analysis, and hierarchical 
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clustering) to detect whether molecular classification of melanoma could indicate 
prognosis.   
We hypothesize that there is a positive correlation between cadherin or catenin 
expression and survival.  The hope is possibly to relieve the need for a sentinel lymph 
node biopsy.  Technicians could perform immunohistochemical staining to detect the 
aggressiveness of malignancy, and then determine the likelihood that the melanoma will 
spread to other areas of the body.  Therefore, patients might be spared the painful – and 
not always predictive – procedure of sentinel lymph node biopsy.  Additionally, 
physicians will be able to better predict the aggressiveness of each specific case of 
melanoma.  As successful treatment modalities are identified, clinicians will be able to 
more confidently guide patients to patient-specific treatment plans.  Hopefully the 
patients who need adjuvant therapy will be more readily identified. 
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Methods 
Melanoma Tissue Microarrays (TMAs) 
 In order to systematically classify large cohorts of patients based on molecular 
expression of proteins, scientists must have an effective and reproducible means of 
performing these potentially large experiments.  One such method employs the use of 
tissue microarrays to decrease the amount of tissue used in each experiment as well as 
ease the required work and time demands that traditional slides would demand.  Figure 2 
illustrates the steps to create a TMA.  
 
 
Figure 2 (35).  Tissue Microarray Construction.  After a pathologist identifies the area 
of interest, a core of sample tissue is drilled using a precision arraying instrument.  The 
cores are placed in a paraffin recipient block.  Using a tape transfer system, 5-micrometer 
thick sections are sliced from the block and cross-linked to slides.  The final image shows 
an example section of histospots on a slide.  Each histospot is assigned a specific grid 
location used to identify the spot after staining. 
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Some benefits of working with TMA’s include the conservation of human tissue 
which is of limited and coveted supply, and the reduction of slide-to-slide staining 
variability that would be seen if comparing traditional slides.  A downfall is that only a 
small section of original tissue is represented on each slide, and a great percentage of the 
tissue architecture is not represented.  However, representative tissue is carefully selected 
by pathologists when used in a TMA.   
For our study, formalin-fixed, paraffin-embedded specimens from the archives of 
the Yale University Department of Pathology were used to construct YTMA 59.  YTMA 
59 is a compilation of 512 melanoma specimens with nearly complete follow-up for 
every case, including cause and date of death.  All patients were diagnosed between 1959 
and 1994.  The array consists of primary (215), metastatic (283), and local recurrence 
(14) specimens, along with nevi (22) and melanoma cell lines (mm127, mnt1, sk23, 
mel888, mel624, melanocytes1, yugen8, yumac, yumor, yusac2, yusit1, 1241, 1335, 501, 
928) as negative and positive controls, respectively.  Descriptive characteristics of the 
patients and melanoma samples from YTMA59 are summarized in Table 3.     
 
Table 3.  Descriptive statistics of patients with melanoma tissue on YTMA59. 
  N Primary Melanoma Local Recurrence Metastatic Melanoma
Cohort 511 214 14 283 
Age, mean (yrs) 469 57.8 57.6 53.3 
Female 225 111 5 109 
Male 272 102 9 161 
Breslow, mean (mm) 260 2.47 5.20 3.03 
Stage I-IIB 264 158 11 95 
Stage III-IVA 89 30 1 58 
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To construct the TMA, we identified representative areas of melanoma, nevi, or 
cell lines and placed 0.6 mm diameter cores into a recipient block using a precision 
arraying instrument (Beecher Instruments, Silver Spring, MD).  An ultraviolet, cross-
linkable, tape transfer system (Instrumedics Inc., Hackensack, NJ) fastened 5-micrometer 
sections to adhesive slides.   
Each master block has each case represented by a single histospot.  Every 10th 
slide is stained with H&E and reviewed by a pathologist to confirm the diagnosis of 
melanoma.  An internal reviewer observed all histospots during staining.  The slides were 
enveloped with paraffin for storage.  Each slide was cut as needed, but if storage was 
required slides were placed in a nitrogen desiccation chamber to prevent antigen 
oxidation.  We have shown that these methods successfully store slides for up to 3 
months (36). 
Students working in the Rimm Laboratory prior to 2004 collected the patient data 
for YTMA 59.  I assisted with data collection for a new YTMA while working in 2004. 
 
Fluorescent Immunohistochemical Staining 
Fluorescent immunohistochemical staining utilizes immunologic interactions 
between primary and secondary antibodies to link a fluorescent probe to a specific 
protein target.  Coons and colleagues were first to successfully link a fluorescent dye to 
antibodies using the principles of immunohistochemistry (37).   The general principles 
and steps of immunohistochemistry are as follows:  1) antigen fixation: the tissue is 
prepared (usually using formalin or paraformaldehyde) to preserve histological 
architecture and cellular shape; 2) tissue sectioning: typically specimens are embedded in 
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paraffin wax or a whole mount can be prepared to give 3-dimensional cellular 
information; 3) antigen retrieval: methods such as pressure-cooking slides in citrate 
buffer or reagents like proteinase K, trypsin, or pepsin are used to disrupt the protein 
cross-links from formalin fixation to unveil hidden epitopes; 4) blocking of background 
staining: hydrogen peroxide will prevent non-immunologic staining; 5) direct or indirect 
linkage of antibody to antigen and detection source: direct antibodies have a detection 
source previously bound to the antibody, while indirect methods use a primary antibody 
to bind to antigen, then a secondary antibody binds to primary antibody because it is 
against the IgG of the specific animal in which the primary antibody was grown; indirect 
linkage allows for detection amplification; the secondary antibody is typically conjugated 
to biotin or horseradish peroxidase, and finally colorimetric agents such as DAB, or 
linked fluorescent dyes such as cy5-tyramide, are added to allow for detection (38). 
With the use of an epiflourescent microscope, we are able to locate molecular 
targets.  The natural tissue architecture is maintained because of in situ hybridization, 
allowing us a more accurate assessment of molecular targets.  We chose automated 
quantitative immunohistochemistry because it even further standardizes the traditional 
methodology of grading staining.  Pathologists typically have relied on manually scoring 
each slide as "0, 1+, 2+, 3+" in staining intensity.  However, this traditional visual 
assessment of each slide is time-consuming and subject to bias from individual raters.  
Our laboratory has created a reliable system of automated quantitative 
immunohistochemistry to forgo the downfalls of traditional manual staining techniques 
(39). 
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Each TMA slide was first deparafinized using xylene, followed by one wash in 
100% ethanol and then further diluted washes (95%, 90%, etc.) down to 50% ethanol and 
50% water for three minutes at each dilution.  The slides were transferred to deuterium 
depleted (dd) water and boiled in a pressure-cooker in 6.5 mM Na-citrate buffer (pH 6.0) 
for 15 minutes.  Endogenous peroxidase activity was blocked using a solution of using 
absolute methanol with 0.75% hydrogen peroxide for 30 minutes at room temperature.  
The slides were washed with tris-buffered saline (TBS) twice, and then incubated with 
0.3% bovine serum albumin (BSA)/1x TBS to diminish nonspecific background staining.  
The following primary antibodies were used on separate slides at the following dilutions: 
mouse anti-α-catenin (Zymed Laboratories, 180225, Clone CAT-7A4) 1:150, mouse anti-
β-catenin (BD Transduction Laboratories, 610153, Clone 14) 1:2500, mouse anti-E-
cadherin (BD Transduction Laboratories, 610181, Clone 36) 1:400, mouse anti-P-
cadherin (BD Transduction Laboratories, 610227, Clone 56) 1:250, mouse anti-N-
cadherin (Zymed Laboratories, 18-0224, Clone 3B9) 1:150, mouse anti-p120-catenin 
(BD Transduction Laboratories, 610133, Clone 98) 1:400.  The proper dilution for each 
primary antibody was determined after staining melanoma test arrays at four different 
dilutions based on values found in the literature.  Envision goat anti-mouse-horseradish 
peroxidase was used as a secondary antibody.  All antibodies used in this study have been 
previously validated and used by our laboratory (40-42).  Subcellular localizations are all 
consistent with previous descriptions for each antigen. Using 4', 6-diamidino-2-
phenylindole (DAPI) staining (1:100) we were able to differentiate each cell’s nucleus 
from cytoplasm.  S-100 was used to stain each case and define a region of interest (mask) 
for the melanoma within each sample histospot at a dilution of 1:650 (DAKO) (43). 
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Staining for gamma-catenin at various dilutions was attempted, but due to 
nonspecific staining the additional protein marker was abandoned.  Additionally, because 
melanoma tissue rarely expresses gamma-catenin the possibility exists that staining may 
have been accurate but not sufficient for our analysis. 
I worked with a fellow medical student, Aaron J. Berger, to learn the 
immunohistochemistry technique.  For nearly half of the markers, we worked together on 
the staining.  I also assisted him in staining other potential markers at various 
concentrations for his dissertation.  Besides my own adhesion protein antibodies, I 
performed the staining and titrations for the following markers while occasionally 
utilizing Berger’s assistance:  HIF-1alpha, ki67, p16, p21, p27, p53, cyclin D1, nm23.  
Laboratory technicians, including Kyle DiVito, Melissa Cregger, Summar Siddiqui,, 
occasionally mixed solutions for general staining purposes.  I created my own dilutions of 
antibodies. 
 
Quantification 
Histospot images were acquired using a modified computer-controlled 
epifluorescence microscope (Olympus BX51 microscope with automated x, y, z stage 
movement.) and an Olympus Motorized Reflected Fluorescence System and software (IP 
lab v3.54, Scanalytics, Inc.), with an attached Cooke Sensicam QE High Performance 
camera.  The customized system automatically obtained images at the specified 
wavelengths. 
Dr. Robert Camp of our laboratory created a custom program that “finds” all 
histospots and creates a system of identification utilizing the rows and columns.  The 
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“spotfinder” algorithm uses size criteria to initially find all the locations, and then uses 
the known grid system to identify the other tissue samples.  The coordinates of all the 
histospots are recorded to be used for linkage to clinical data (Figure 3). 
 
Figure 3. Microarray image after spotfinder algorithm. 
 
 
Tissue staining was graded on a scale from 0 to 4095 using the program AQUA 
(Automated Quantitative Analysis), designed by Dr. Robert Camp.  It allows for 
computerized accession and quantification of tissue microarray protein levels.  The Rapid 
Exponential Subtracting Algorithm (RESA) produces a “non-nuclear mask” by 
subtracting the DAPI (nuclei) image from the larger S100 (tumor mask) image for each 
histospot.  AQUA and RESA have been previously described by Camp et al. (Figure 4) 
(39). 
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Figure 4 (adapted from Aaron J. Berger 2006). AQUA software.  The panels above 
show the title pane, score window, settings window, algorithm window and four image 
windows with raw and processed data from one example histospot.   The upper left image 
shows an original keratin immunofluorescence picture before the tumor mask is applied.  
The upper right image window illustrates the tumor mask.  The lower right pane 
demonstrates the non-nuclear (cytoplasm) mask. 
 
In brief, the computer and microscope system utilize two images, one taken at the 
appropriate plane of focus and an additional image taken below the previous plane.  The 
second image is essentially just below the base of each 5-micron section of tissue.  The 
two high quality, monochromatic 0.5 micron resolution images allow for the distinction 
of large subcellular compartments such as nuclei (39).     
AQUA uses the following two algorithms, RESA and PLACE (pixel-based locale 
assignment for compartmentalization of expression), to:  1) create each “tumor mask,” or 
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identify tumor within other tissue; 2) identify large subcellular compartments; and 3) 
quantify and locate biomarker florescence within tumor mask. 
Using co-localization to measure the amount of target within the previously 
defined “mask,” an AQUA score is determined for the entire tumor area, as well as for 
the nucleic area and “non-nuclear” area (i.e. mostly cytoplasmic area).  AQUA scores are 
continuous variables and defined as (intensity of target)/area (Figure 5). 
 
Figure 5 (adapted from Aaron J. Berger 2006). AQUA algorithm for melanoma.  
The first column of images is raw, while the last column is post-AQUA melanoma 
protocol.  The first row of windows shows S100 protein expression (Alexa 488), a marker 
specific for melanoma in epithelial tissue.  The expression of S100 differentiates tumor 
from surrounding tissue.  The individually produced tumor mask is captured as a binary 
image, and further refined by removing small objects and filling holes.  Next AQUA 
relies on the DAPI image to discriminate nuclei.  Using RESA (Rapid Exponential 
Subtracting Algorithm), the DAPI (nuclei) image is subtracted from the larger S100 
(tumor mask) image to produce a non-nuclear (cytoplasm) mask.  The final images in the 
bottom horizontal row show RESA application to the target (HDM2) image.  Cy5 
immunofluorescence is used to capture specific marker staining.  RESA uses exponential 
subtraction to obtain the most precise quantification via pixel-based locale assignment for 
compartmentalization of expression (PLACE algorithm).  Following image acquisition, 
the aforementioned masks are applied.  The target localization image in the lower right 
corner illustrates the final image used to quantitate the AQUA score, which is 
intensity/area. 
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Aaron Berger assisted me with the initial marker acquisitions, but after learning 
the programs I set up and ran AQUA for my markers. 
 
Statistical Analysis 
Only histospots with tumor covering greater than 5% of tissue area were included 
in our analysis.   The specimens were linked to their respective prognostic information 
using Cruella online.  We used JMP 5.0.1, Statview 5.0.1 (SAS Institute Inc., Cary, NC), 
and X-Tile software (http://www.tissuearray.org/rimmlab/xtile.html) for data analysis.  
Survival curves were created using the Kaplan-Meier method (univariate analysis)(44).  
The values of cadherin expression in the non-nuclear mask were used whenever these 
markers could be analyzed separately to allow for more precise data interpretation.  The 
Cox proportional hazards test was used for univariate and multivariate analysis.  Non-
normally distributed raw data was normalized using the natural log before individual 
parametric tests.  Otherwise, raw AQUA scores were always used during analysis.  
Significant results required a p value of <0.05.   
 
Non-Parametric Spearman Rho Scatterplot Matrix 
 A scatterplot matrix shows the magnitude of similarity or dissimilarity among 
numerous markers.  The matrix system allows for the comparison of each individual 
marker to every other marker by first ranking the data, then calculating the scatterplot 
matrix.  The rho value denotes the degree of similarity, or “linear relationship,” and can 
be positive or negative suggesting the type of association (direct or inverse) (45,46). 
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X-Tile Software 
To create the Kaplan-Meier survival curves, we used X-Tile software to find the 
optimal binary cut-point in our data.  We split our cohort into a training and validation 
set.  Each set contained half of our original cohort and was outcome matched.  The 
training set was used to define low- or high-expressing melanoma tissue for each specific 
marker.  We then tested the cut-point on the validation set to assess the prognostic value 
of each marker (47).   
 
Hierarchical Clustering 
For hierarchical clustering, we first applied the natural log to tumor mask AQUA 
scores to normalize raw data.   Z-scores were produced from the normalized data and 
values were analyzed with Cluster 2.11.0.0 and Gene TreeView 1.60 
(http://rana.lbl.gov/EisenSoftware.htm).  Using 80% present as the filter, 395 patients out 
of 514 were included in the tree following average link clustering.  Four minor clusters 
equidistant from the patient cluster were arbitrarily chosen and analyzed with Kaplan-
Meier survival curves.  
Hierarchical clustering is a way to separate sub-groups of patients by similarity of 
their expression profile.  The idea is to cluster patients who are more similar to each other 
than everyone else in the cohort by comparing each patient’s expression profile with all 
other patient’s profiles.  The analysis creates sub-populations by minimizing differences 
within clusters and maximizing differences between different clusters.  The process of 
clustering produces a dendrogram of patient profiles and biomarkers.  The branch length 
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describes the extent of similarity.  Different “clusters” may be chosen to group patients 
by selecting a point along the length of the patient dendrogram.   Any point may be 
chosen depending on how similar or dissimilar the groups are desired to be.  
Additionally, the biomarkers also are placed in a dendrogram that suggests similarity or 
dissimilarity of staining patterns.  Patients, with their expression profiles, are placed in 
order to create a “heat map.”  The color and intensity (typically red denotes high 
expression and green shows low expression) describes the quantity of protein in each 
tissue sample.  (48,49).   
I performed all the statistical analysis with the occasional assistance from David 
Rimm, M.D., Ph.D., Robert Camp, M.D., Ph.D., Annette Molinaro, Ph.D., Jena Giltmore, 
and Melissa Cregger. 
 
Results 
 Figure 6 illustrates the final image after RESA, PLACE, and AQUA algorithms 
are applied to the images captured from the fluorescent stains.  The marker in this image, 
E-cadherin, demonstrates the mostly membranous staining of cadherins.  Unfortunately 
our image resolution does not allow for the distinction between membranous and 
cytoplasmic staining.   
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Figure 7.  E-Cadherin immunofluorescence after AQUA algorithms of a single histospot. 
 
Figure 7 demonstrates the image captured from S-100 staining, used to identify 
the area of tumor.  Notice normal stroma that is not stained surrounding melanoma tissue.  
The photo is captured later translated into a binary image, not shown here. 
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Figure 7.  S-100 immunofluorescence of a single histospot. 
 
Figure 8 shows the range and distribution of AQUA scores for alpha-catenin, 
beta-catenin, p120-catenin, N-cadherin, E-cadherin and P-cadherin.  N-cadherin 
expression clearly was not expressed in a normal distribution; therefore, raw values were 
normalized prior to analysis with parametric tests.    
 
S-100 
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Figure 8.  AQUA scores showing range and distribution for alpha-catenin, beta-
catenin, p120-catenin, N-cadherin, E cadherin and P-cadherin.  
 
 
 Table 4 shows the average AQUA values for each sub-group of histospots for all 
analyzed markers.   
Table 4. Average tumor mask staining of nevi, primary melanoma, local recurrence melanoma, 
metastatic melanoma, and melanoma cell lines from YTMA59.   
 Alpha-catenin Beta-catenin P120-catenin E-cadherin N-cadherin P-cadherin
Nevi 156.512 901.949 358.414 534.688 248.896 641.745 
Primary Melanoma 191.239 760.894 286.61 583.53 274.754 566.732 
Local Recurrence 222.057 617.096 311.029 625.671 214.202 554.722 
Metastatic Melanoma 218.386 703.36 322.897 488.782 197.335 544.113 
Melanoma Cell Lines 320.399 1176.666 627.625 888.974 383.261 695.402 
ANOVA p-value <0.0001 <0.0001 <0.0001 0.0004 0.0003 <0.0001 
 
Unpaired T-Tests 
We found that mean alpha-catenin expression was the lowest in nevi (156.512) 
and the highest in melanoma cell lines (320.399).  Expression was increased in the 
primary melanoma patient population (191.239) and significantly increased in the 
metastatic group (218.386) when compared to regular nevi (p=0.0131).  The local 
recurrence population’s mean (222.057) was most similar to the metastatic’s mean.  The 
averages of primary and metastatic melanomas were significantly different (p=0.0055) 
(Tables 4 and 5). 
Beta-catenin also had the highest average expression in melanoma cell lines 
(1176.66), but the tissue with the lowest expression was local recurrence melanoma 
(617.096) followed by metastatic melanoma (703.36) and then primary melanoma 
(760.894).  The average nevi and primary tissues had a significant mean difference of 
 - 30 - 
141.046 (p=0.031).  Primary and metastatic tissues also were significantly different for 
beta-catenin (0.0128).  Nevi and metastatic melanoma average scores were significantly 
dissimilar with the largest difference seen in all the scores of 198.59 (p=0.0005). 
P120-catenin expression was absolutely the highest in metastatic melanoma tissue 
(627.625).  Primary melanoma tissue showed the lowest average values with a mean of 
286.61.  Nevi showed average expression of p120-catenin that was much lower than 
metastatic tissue, however higher than all other specimens (358.414).  The only 
interesting comparison of average values that was significant was the difference between 
primary and metastatic tissue (p=0.0313). 
E-cadherin followed the pattern of extremely high average expression within 
melanoma cell lines (888.974).  Metastatic tissue actually had the lowest mean expression 
of 488.782.  Only the difference between primary and metastatic tissue was significant 
for E-cadherin (94.748, p=0.0055).   
N-cadherin also had the highest mean expression within melanoma cell lines 
(383.261).  Metastatic melanoma was the lowest average expresser (197.335).  The 
difference between primary and metastatic tissue averages was significant (77.419, 
p<0.0001). 
Finally, P-cadherin likewise had the highest average AQUA score expressed in 
melanoma cell lines (695.402).  Metastatic melanoma expresses the lowest average score 
of 544.113.  A trend of decreasing average scores was seen from nevi to primary 
melanoma, to local recurrence, to metastatic melanoma.  All comparisons of nevi to 
primary tissue, primary to metastatic, and nevi to metastatic were significant (75.013, 
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p=0.0145; 22.619, p=0.0311; and 97.632, p=0.0003, respectively).  This trend was only 
seen with P-cadherin. 
 
Table 5.  Unpaired t-tests of all markers. 
Alpha-catenin Mean Difference T value P Value 
Nevi: Primary -41.333 -1.407 0.1053 
Primary: Metastatic -29.267 -2.656 0.0055 
Nevi: Metastatic -70.6 -2.237 0.0131 
     
Beta-catenin Mean Difference T value P Value 
Nevi: Primary 141.056 2.173 0.031 
Primary: Metastatic 57.534 2.499 0.0128 
Nevi: Metastatic 198.59 3.51 0.0005 
     
P120-catenin Mean Difference T value P Value 
Nevi: Primary 71.804 1.71 0.0891 
Primary: Metastatic -36.287 -2.161 0.0313 
Nevi: Metastatic 35.517 0.804 0.422 
    
E-cadherin Mean Difference T value P Value 
Nevi: Primary -48.842 -0.528 0.5985 
Primary: Metastatic 94.748 2.794 0.0055 
Nevi: Metastatic 45.905 0.509 0.6111 
    
N-cadherin Mean Difference T value P Value 
Nevi: Primary -25.858 -0.524 0.6011 
Primary: Metastatic 77.419 3.978 <0.0001 
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Nevi: Metastatic 51.562 1.131 0.2588 
     
P-cadherin Mean Difference T value P Value 
Nevi: Primary 75.013 2.466 0.0145 
Primary: Metastatic 22.619 2.163 0.0311 
Nevi: Metastatic 97.632 3.689 0.0003 
 
 
Non-Parametric Spearman Rho Scatterplot Matrix 
 Correlations of raw AQUA scores among all six protein markers are shown in 
Figure 9.  P-cadherin and beta-catenin express the highest rho value (r=0.5238, 
p<0.0001).  Beta-catenin shares a similarly strong correlation with E-cadherin (r=0.4494, 
p<0.0001).  E-cadherin correlates positively with alpha-catenin (r=0.3592, p<0.0001).  
P120-catenin shares positive correlations with both alpha and beta-catenins (r=0.3480, 
p<0.0001 and r=0.3638, p<0.0001, respectively).   
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Figure 9.  Non-parametric Spearman rho scatterplot matrix depicting similarity in 
staining intensity of measured cadherins and catenins.  P-cadherin and beta-catenin 
correlate with a rho of 0.5238 (p<0.0001).  E-cadherin and beta-catenin increase at 
proportional rates (rho=0.4494, p<0.0001).  E-cadherin likewise corresponds with alpha-
catenin (rho=0.3592, p<0.0001).  All associations are significant except N-cadherin when 
paired with E-cadherin, P-cadherin and beta-catenin and the pairing of P-cadherin and 
alpha-catenin. 
 
 However, N-cadherin shows an inverse correlation with all analyzed markers.  
Besides being reciprocally related, the mesenchymal cadherin shows some of the weakest 
correlations with other proteins.  Although not significant, the correlations with beta-
catenin and E-cadherin are the lowest (r= -0.0451, p=0.8156 and r= -0.0573, p=0.1156, 
respectively). 
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After separating low- and high-expressing melanoma tissue using cut-points 
created from analysis of our training cohort (50% of original cohort) with X-Tile, raw 
AQUA scores of non-nuclear N- and E-cadherin significantly predicted patient survival 
(Figure 10) (p=0.0222 and p=0.0233, respectively).  The low expressing N-cadherin 
(non-nuclear) group had a RR=1.883 (95% CI of 1.099-3.226, p=0.0212).  The RR of E-
cadherin (non-nuclear) for the low expression group was 1.532 (95% CI of 1.057-2.221, 
p=0.0243).  Univariate analyses of other markers are summarized in Table 5.  E- and N-
cadherin (non-nuclear) expression did not retain significance when analyzed with 
Breslow, age, and gender. 
Figure 10.  Kaplan-Meier survival curves using cut-points created with X-tile for 
non-nuclear expression of E-cadherin and N-cadherin.  The validation cohort was 
significant for N-cadherin (non-nuclear) when separating high and low expressing 
melanomas at an AQUA score of 366 (p=0.0222).  The E-cadherin (non nuclear) 
validation set was significant between high and low expression groups using the X-tile 
produced cut-point of 426 (p=0.0233). 
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Table 5.  Cox Proportional Hazards univariate and multivariate analysis of markers using X-tile 
produced cut-points. 
Univariate Analysis     
Variable (Low expression) N Relative Risk 95% Confidence Interval P Value 
N-cadherin, non-nuclear 201 1.883 1.099-3.226 0.0212 
E-cadherin, non-nuclear 164 1.532 1.057-2.221 0.0243 
P-cadherin, non-nuclear 207 1.168 0.784-1.740 0.4447 
Alpha-catenin 208 0.904 0.644-1.268 0.5578 
Beta-catenin 210 1.386 0.908-2.114 0.1300 
P120-catenin 186 1.224 0.860-1.740 0.2615 
Multivariate Analysis N Relative Risk 95% Confidence Interval P Value 
Breslow depth (mm) 1.094 0.999-1.198 0.0529 
Age at diagnosis (yrs) 1.006 0.985-1.027 0.5886 
Gender (female) 0.658 0.351-1.235 0.1928 
N-cadherin, non-nuclear (low) 
94 
1.77 0.835-3.754 0.1365 
Multivariate Analysis N Relative Risk 95% Confidence Interval P Value 
Breslow depth (mm) 1.109 1.012-1.215 0.0272 
Age at diagnosis (yrs) 1.018 0.744-2.616 0.1429 
Gender (female) 0.775 0.399-1.504 0.4505 
E-cadherin, non-nuclear (low) 
69 
1.489 0.785-2.824 0.2223 
 
Hierarchical Clustering 
 Hierarchical clustering organized melanoma patients into four distinctive clusters 
that individually shared similar expression profiles (Figure 11A).  Only patients who had 
sufficient protein expression with tumor covering greater than 5% area of the histospot in 
at least five of six protein markers were included in average-linked clustering.  Four 
clusters were arbitrarily chosen at an equidistant point.  Cluster 1 includes 167 patients 
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who have high expression of alpha-catenin and E-cadherin, but relatively low expression 
of N-cadherin.  These patients had the second highest survival rate of ~25% at 20 years 
(Figure 11B).  Cluster 2 has the lowest survival at 5 years (~27%) and the second lowest 
at 20 years (~22%).  The group includes 31 patients with generally low expression of 
alpha-catenin and E-cadherin.  Cluster 3 has relatively low or average expression of all 
three cadherins and all three catenins.  The survival of these 127 patients is the lowest of 
the four clusters at 20 years (~12%).  Cluster 4 expresses the highest relative levels of N-
cadherin compared to other clusters.  The 36 patients in cluster 4 had the highest survival 
at 5 years (~68%) and 20 years (~50%).  The survival curves were significant with 
p=0.0003. 
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Figure 11A.  Hierarchical cluster and survival curve of melanoma patients based on 
expression of indicated cadherins and catenins.  
A.  The hierarchical cluster produced by TreeView 1.60 and Cluster 2.11.0.0 (Eisen 
Software, Berkeley, CA) includes 361 patients who had sufficient protein expression with 
tumor covering greater than 5% area of the histospot in at least five of six protein 
markers.  Four clusters were arbitrarily chosen at an equidistant point.  Red denotes high 
expression, black is average, and green shows low expression.  Cluster 1 (blue) shows 
167 patients characterized by high expression of alpha-catenin and E-cadherin with 
relatively low expression of N-cadherin.  Cluster 2 (red) is composed of 31 patients who 
had melanomas with generally low expression of alpha-catenin and E-cadherin.  Cluster 3 
(purple) is described by relatively low or average expression of all three cadherins and all 
three catenins in a total of 127 patients.  Cluster 4 (orange) has the highest relative levels 
of N-cadherin compared to the other patients in the cohort.  Other protein expression is 
varied but generally decreased in the group of 36 patients.  
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Figure 11B.  Kaplan-Meier analysis of the four clusters with 20-year follow-up shows 
significantly different survival rates (p=0.0003).  Cluster 1 had a mean survival of 103.5 
months, cluster 2 averaged 37.8 months, cluster 3 averaged 75.0 months, and cluster 4 
had a mean of 85.1 months.   
 
The adhesion protein dendrogram created from clustering is perhaps our most 
interesting result.  In accordance with the Kaplan-Meier survival curve and Spearman rho 
scatterplot matrix, N-cadherin is the most dissimilar to other markers.  P-cadherin and 
beta-catenin share the most similarity.   
 
 
Discussion 
Patterns of Expression 
 The average expression of all three cadherins was the lowest in metastatic tissue.  
The next lowest group of tissue was from local recurrence for N- and P-cadherin.  Local 
recurrence tissue is viewed by some as more similar to a metastasis than a primary tumor 
because of its association with a higher death rate, and this molecular data may support 
that classification (15).    
 Cell lines of melanoma showed the overwhelmingly highest averages of 
expression for all markers (Table 4).   Unfortunately, there was no corresponding pattern 
 - 39 - 
of expression in a particular type of in situ tissue.  As useful as cell lines can be in other 
studies, our results may reflect the fact that cell lines of melanoma tissue have acquired 
many mutations that deregulate normal cellular processes.  These cells lines may have 
lost a large number of traits that give them similarity to unmanipulated melanoma tissue. 
 In Table 5, t-tests show that primary tissue mean expression is statistically 
different from metastatic melanoma tissue for every marker.  This data further suggests 
that adherens junctional protein regulation is altered as a tumor progresses from a 
melanoma in situ to a more aggressive type, such as one that would cause metastatic 
disease. 
 
Biological Interactions of Cadherins and Catenins 
Our results summarize previously know biological interactions among cadherins 
and catenins.  We have shown that P-cadherin and beta-catenin have extremely similar 
expression profiles through Spearman rho correlations and a dendrogram after 
hierarchical clustering.  According to our data p120-catenin and alpha-catenin also share 
similarity to the former proteins (Figure 11A).  The high, positive rho values further 
strengthen the argument, although alpha-catenin and P-cadherin are not significant in the 
scatterplot matrix.  Our findings reinforce the known binding of alpha-catenin to beta-
catenin because of their similar expression profiles and significant positive rho of 0.2280 
(Figure 9).  Likewise, alpha-catenin is linked to E-cadherin via a connecting protein, 
beta-catenin (alpha-catenin to E-cadherin rho=0.3592, p<0.0001, and beta-catenin to E-
cadherin rho=0.4494, p<0.0001) (50,51).  When downregulation of any one linked 
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cadherin(s) or catenin(s) occurs, it is logical that other proteins in the complex would 
follow suit. 
Average-linked clustering produced a cluster tree highlighting the biological 
interactions among the analyzed cadherins and catenins.  N-cadherin separates early from 
the other markers, suggesting that its expression is independent of the other proteins.  The 
two markers that are most closely linked to N-cadherin are E-cadherin and alpha-catenin.  
Many researchers have highlighted the interaction between E and N-cadherin in 
melanoma (29,52).  Kuphal and Bosserhoff show that the loss of E-cadherin stimulates 
the up-regulation of N-cadherin via induction of NFĸB.   
 
Survival Analysis 
We found that moderately high (or maintained) expression of N-cadherin and E-
cadherin correlated with improved survival significantly.   Our survival curves showing 
low expression of E-cadherin in non-nuclear compartments confirms previous findings 
that low E-cadherin is a marker of poor prognosis (27).  High expression of alpha-
catenin, p120-catenin, and P-cadherin was associated with better survival, although not 
significant (Table 5).  This discovery was contrary to some findings described in the 
literature, but these studies were mostly qualitative and often did not relate findings to 
prognosis (29,33,34).  We believe that if we could distinguish membranous staining from 
cytoplasmic staining, we would see alpha-catenin expression only within the cytoplasm – 
and not the membrane – in these metastatic cells.   The potential decrease of catenin at 
the adherens junction explains the increased mobility of metastatic cells. 
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Furthermore, Kaplan-Meier curves from hierarchical cluster-generated 
subpopulations of patients confirmed our hypothesis that patients with overall decreased 
expression of adherens junctional proteins have decreased survival, possibly due to the 
cancer’s ability to detach from its environment.  This subtype of melanoma is consistent 
with less differentiation and increased motility ability.  Cluster 3, the subgroup with 
generally low expression of all tested adhesion proteins, has the absolute lowest survival 
rate from our cohort (Figure 11B).   
The overall decrease in N-cadherin and beta-catenin expression in metastatic 
melanoma suggests that adherens junctions deteriorate in cells that become metastatic.    
Our findings support one of the requirements for metastatic melanoma; malignant cells 
must be able to disassociate from neighboring cells to become metastatic. 
We found that some of the select cadherins and catenins were up- and down- 
regulated in a fashion that was not found to be independently significant.  However, when 
the six markers were analyzed in an algorithm that made use of all quantitated data, we 
found that patients could be organized into distinct subgroups.  These groups differed by 
the amount and type of adhesion-complex protein expressed.  When these groups were 
plotted on a Kaplan-Meier curve, the prognosis of one population was significantly 
different than other populations.   
Just as the five proteins described above are similar in expression and allow us to 
group patients into clusters with poor survival, strong expression of N-cadherin defines a 
subpopulation of patients with the best survival of our cohort.  Our findings are contrary 
to previously reported epithelial-to-mesenchymal transition (EMT) studies.  The EMT 
describes the change in expression of adhesion proteins when a malignancy transforms 
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into a more aggressive tumor.  Some literature suggests that malignant conversion occurs 
via NFĸB signaling in melanoma.  Downregulation of E-cadherin stimulates N-cadherin, 
which is described as “cadherin switching” (53).  However, the increase in N-cadherin is 
shown in cell lines and has not been analyzed in regard to prognosis.  Our data 
summarizes a subpopulation of melanoma patients, and the EMT melanomas may be 
describing a different class.  Additionally, neural crest derived melanomas may be 
entirely different from the epithelial carcinomas that have previously shown cadherin 
switching.  Cadherin switching may indicate more aggressive disease in epithelial derived 
tumors, but in melanomas that are derived from the neural crest, retaining N-cadherin 
may indicated a more highly differentiated tumor since the expression resembles a mature 
melanocyte. 
Limitations to our work include the problems encountered when dividing a cohort 
into training and validation sets.  Because we used a separate set of patients to determine 
cut points for the validation set, we did not train the X-Tile tests on the same cohort of 
patients.  This should ensure the quality of our findings, however limiting the final 
number of patients that could be included in analysis.  Other limitations include the 
inability to directly measure cytoplasmic, or even more specifically membranous, 
expression of cadherins.  While a more precise “membranous mask” would give our 
experiments further accuracy, the catenin proteins were properly measured in the entirety 
of the tumor.  Catenins can be found in the cytoplasm and nucleus, as well as attached to 
E-cadherin complexes or individually placed within the cell (50).  Although we attempted 
to include gamma-catenin in our studies, heterogeneous staining presumably due to a 
nonspecific antibody prevented us from presenting a more complete picture of the 
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adhesion proteins in melanoma.  Alternatively, gamma-catenin may be expressed at very 
low levels in melanoma, and our staining methods did not allow for accurate assessment. 
In summary, the expression profile of tumors reflects known biological 
interactions of cadherins and catenins.  Our scatterplot matrix and biomarker dendrogram 
exemplified the relationships.  Molecular classification using AQUA technology may 
identify less aggressive sub-types of melanoma.  
We identified at least two subclasses of melanoma that correlate with survival: 1) 
one with strong expression of N-cadherin, which identifies patients with the best survival 
of our cohort; and 2) a second subclass with a very poor outcome that includes two 
distinctive molecular classes:  A) one with downregulation of essentially all the cadherin-
catenin complex proteins as would be seen in a poorly differentiated tumor; and B) 
another that includes patients with high levels of all the cadherin-catenin proteins 
consistent with an epithelioid type of melanoma. 
More recent work in our laboratory has shown that after stratifying the cohort into 
primary and metastatic disease, our results hold true when analyzing simply primary 
tissue.  These results would allow for even earlier identification of aggressive subtypes of 
melanoma, therefore, possibly alleviating the need of a SLNB.  Clinicians would be able 
to recognize patients with more aggressive forms of melanoma even before metastasis 
occurs, allowing quicker and possibly more targeted forms of therapy.  Immediate 
practical application of this work includes the ability to classify patients into clearer and 
more precise sub-groups based on the aggressiveness of disease.  This will allow 
clinicians to determine which patients may benefit from certain therapeutics, when 
successful adjuvant therapies are identified.    
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 Our findings are consistent with Bittner, Onken, and Alonso (10,11,14).  Our 
study expands on their work by showing that molecular classification of melanoma 
correlates with survival and can indicate prognosis.   Our bench-work science clearly can 
be applied to the bedside, and may benefit melanoma patients in the near future. 
Future studies in this area could use larger cohorts of purely primary tissue to 
further strengthen the power of the analysis.  Once a validated antibody of gamma-
catenin can effectively stain melanoma tissue, more complete analysis of the cadherin 
and catenin family can occur.  Other markers such as phosphorylated beta-catenin and 
cadherin 11 can be explored as well.  We had difficulty obtaining precise and accurate 
staining with these antibodies.  Additionally, further refinements in technique will allow 
for quantification of biomarkers within more precise areas of the cell, such as purely 
cytoplasmic, membranous, or nuclear-membranous staining.   Further statistical 
exploration with a larger cohort might produce a predictor model that can be used in 
clinical practice.  Later studies could use aggressive-disease melanoma tissue identified 
through the predictor model to test the efficacy of treatment modalities.  Adjuvant 
therapy is only used in late stages of melanoma, but early treatment to this subgroup of 
patients might prove to be more effective.  Furthermore, treating specific subgroups of 
melanoma patients might reveal a higher response rate and greater effect on survival if 
we are able to identify subtype-specific treatments, like the advancements seen in 
estrogen receptor positive breast malignancies. 
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